Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

Guggenheim reaffirmed their buy rating on shares of CyberArk Software (NASDAQ:CYBR – Free Report) in a research note issued ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

LG and the Guggenheim New York proudly announce Ayoung Kim as the 2025 LG Guggenheim Award recipient. Kim is the third artist to be recognized as part of the LG Guggenheim Art and Technology ...

The artist is known for creating futuristic, interactive environments that reflect on contemporary geopolitical and ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

As previously reported, Guggenheim analyst Gregory Francfort upgraded Wingstop (WING) to Buy from Neutral with a $280 price target Despite ...

The Plaza Hotel suite where Frank Lloyd Wright resided during construction of the Guggenheim Museum is up for sale for $18.9 ...

The award is part of the LG Guggenheim Art and Technology Initiative, a five-year, multifaceted collaboration designed to research, honor, and promote artists working at the intersection of art ...